MIST Milestone Pharmaceuticals Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1408443 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-68.7%
TTM EPS YoY6.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-1,370.6%
ROA-78.2%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets103.8%
Debt / equity—
Current ratio6.27x
Interest coverage-7.62x
Cash quality & payout
Operating cash flow / net income0.78x
Accruals ratio-16.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $18.11M | $14.36M | $31.05M | $39.83M | $38.67M |
| SG&A expense | $17.27M | $16.74M | $15.93M | $15.72M | $12.40M |
| Operating income | -$62.14M | -$42.10M | -$61.10M | -$59.64M | -$43.07M |
| Interest expense | $3.84M | $3.58M | $2.55M | — | — |
| Pretax income | -$63.06M | -$41.52M | -$59.69M | -$58.39M | -$42.85M |
| Net income | -$63.06M | -$41.52M | -$59.69M | -$58.39M | -$42.85M |
| EBITDA | -$62.03M | -$42.00M | -$61.01M | -$59.55M | -$42.98M |
| EPS (basic) | -0.75 | -0.67 | -1.39 | -1.38 | -1.02 |
| EPS (diluted) | -0.75 | -0.67 | -1.39 | -1.38 | -1.02 |
| Balance sheet | |||||
| Cash & equivalents | $73.05M | $25.31M | $13.76M | $7.64M | $114.14M |
| Short-term investments | $32.91M | $44.38M | $52.24M | $56.95M | $0 |
| Inventory | $648,000 | — | — | — | — |
| Current assets | $111.92M | $73.93M | $73.03M | $71.80M | $118.92M |
| PP&E, net | $511,000 | $197,000 | $277,000 | $257,000 | $215,000 |
| Total assets | $113.56M | $75.50M | $75.23M | $74.48M | $119.85M |
| Current liabilities | $13.98M | $8.13M | $7.23M | $6.14M | $6.78M |
| Long-term debt | $57.19M | $53.35M | $49.77M | — | — |
| Total debt | $57.19M | $53.35M | $49.77M | — | — |
| Total liabilities | $71.79M | $62.35M | $58.45M | $8.13M | $7.25M |
| Shareholders' equity | $41.77M | $13.15M | $16.77M | $66.35M | $112.60M |
| Net debt | -$15.86M | $28.04M | $36.01M | — | — |
| Shares outstanding | 106.24M | 53.35M | 33.48M | 34.29M | 29.90M |
| Cash flow statement | |||||
| Operating cash flow | -$49.04M | -$28.85M | -$46.42M | -$52.47M | -$33.22M |
| Capital expenditure | $302,000 | $33,000 | $112,000 | $272,000 | — |
| Free cash flow | -$49.34M | -$28.88M | -$46.54M | -$52.74M | — |
| Investing cash flow | $11.25M | $8.28M | $4.76M | -$57.12M | $70.00M |
| Financing cash flow | $85.53M | $32.12M | $47.79M | $3.09M | $5.05M |
| Depreciation & amortization | $114,000 | $105,000 | $92,000 | $89,000 | $93,000 |
| Stock-based compensation | $7.46M | $5.78M | $9.53M | $9.05M | $7.28M |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.